問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李岡遠

Recruiting

List

66Cases

2017-02-06 - 2018-12-31

IIT

Phase IV

The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acteylcysteine (NAC)

  • Condition/Disease

    Tuberculosis

  • Test Drug

    Actein

Participate Sites
4Sites

Recruiting4Sites

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

  • Condition/Disease

    idiopathic pulmonary fibrosis

  • Test Drug

    GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2021-02-01 - 2022-06-16

Phase III

ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2019-06-01 - 2024-03-29

Phase IV

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

  • Condition/Disease

    Solid Tumor

  • Test Drug

    IMFINZI (Durvalumab)

Participate Sites
5Sites

Recruiting5Sites

2015-04-15 - 2020-09-30

Phase I

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Condition/Disease

    Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Test Drug

    OBI-833 (Globo H-CRM197)/OBI-821

Participate Sites
4Sites

Recruiting4Sites

李凱靈
Taipei Medical University Hospital

Division of Hematology & Oncology

2023-07-07 - 2025-12-31

Phase I

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ABBV-514ABBV-181 (Budigalimab)

Participate Sites
5Sites

Recruiting5Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB